{
  "docId": "019de073-3800-772b-871e-98f0ed79adc7",
  "docSlug": "3d30d84bb133b7b226440021781a4f91",
  "documentTitle": "23andMe | Investor Presentation Deck | 58 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 58,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3800-772b-871e-98f0ed79adc7/47",
  "deckHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7",
  "deckJsonHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7.json",
  "deckAnchorHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.515,
        "y": 0.18
      },
      "kind": "list",
      "text": "Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models\nGSK'608 is a high affinity monoclonal antibody against CD96\nGSK'608 is currently being evaluated in an ongoing Phase 1 study\nIn January 2022, 23andMe elected to take a royalty option on GSK'608. As a result, GSK is now solely responsible for the development of GSK'608.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d1be450-f277-4746-9583-289944e65606",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "title",
      "text": "The GSK'608 Program is a Prime Example of the Value 23andMe Brings to Drug Discovery and Development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d940e34-cdf8-4b8d-aec9-ccad6213e466",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "94b996e1-9704-40cd-8154-56d5c2ffe75e",
      "evidence": "title/action-title: The GSK'608 Program is a Prime Example of the Value 23andMe Brings to Drug Discovery and Development",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}